IL278616A - - Google Patents

Info

Publication number
IL278616A
IL278616A IL27861620A IL27861620A IL278616A IL 278616 A IL278616 A IL 278616A IL 27861620 A IL27861620 A IL 27861620A IL 27861620 A IL27861620 A IL 27861620A IL 278616 A IL278616 A IL 278616A
Authority
IL
Israel
Application number
IL27861620A
Other languages
English (en)
Other versions
IL278616B2 (en
IL278616B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL278616A publication Critical patent/IL278616A/en
Publication of IL278616B1 publication Critical patent/IL278616B1/en
Publication of IL278616B2 publication Critical patent/IL278616B2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL278616A 2018-05-10 2019-05-10 Methods for the prognosis and treatment management of a disease IL278616B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862669915P 2018-05-10 2018-05-10
PCT/US2019/031858 WO2019217916A1 (en) 2018-05-10 2019-05-10 Methods for prognosis and management of disease

Publications (3)

Publication Number Publication Date
IL278616A true IL278616A (https=) 2021-01-31
IL278616B1 IL278616B1 (en) 2024-10-01
IL278616B2 IL278616B2 (en) 2025-02-01

Family

ID=66655475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278616A IL278616B2 (en) 2018-05-10 2019-05-10 Methods for the prognosis and treatment management of a disease

Country Status (8)

Country Link
US (1) US20210231686A1 (https=)
EP (1) EP3791188A1 (https=)
JP (2) JP7371019B2 (https=)
KR (1) KR20210014109A (https=)
CN (1) CN112424608A (https=)
AU (1) AU2019264996A1 (https=)
IL (1) IL278616B2 (https=)
WO (1) WO2019217916A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612566A4 (en) * 2017-04-21 2021-03-03 Implicit Bioscience Limited CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN113842449B (zh) * 2021-09-08 2024-02-23 乐卫东 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用
WO2025049671A1 (en) * 2023-08-30 2025-03-06 The Methodist Hospital Markers of amyotrophic lateral sclerosis survival and uses thereof
JPWO2025058005A1 (https=) * 2023-09-15 2025-03-20

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
AU667462B2 (en) * 1990-11-30 1996-03-28 Monoclonetics International Incorporated Methods for the diagnosis of chronic lower back and cervical pain
ATE335072T1 (de) 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US20010041349A1 (en) 2000-04-17 2001-11-15 Andrew Patron Protein expression system arrays and use in biological screening
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
AU2002220236A1 (en) 2000-11-09 2002-05-21 Bionova Pharmaceutials, Inc. A method for identifying the proteome of cells using an antibody library microarray
US7264967B2 (en) 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
EP1360490B1 (en) 2001-01-23 2011-12-21 President and Fellows of Harvard College Nucleic-acid programmable protein arrays
WO2003062444A2 (en) 2001-11-13 2003-07-31 Emory University Array systems and methods
US7030126B2 (en) * 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
EP1502102B1 (en) 2002-03-11 2009-01-14 caprotec bioanalytics GmbH Compounds and methods for analyzing the proteome
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CA2566101C (en) * 2004-05-11 2013-05-21 Mochida Pharmaceutical Co., Ltd. Novel soluble cd14 antigen
CA2754741C (en) * 2009-03-11 2019-02-12 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
EP2501720A2 (en) * 2009-11-18 2012-09-26 Lascco SA Ifn inhibitors in the treatment of motoneuron diseases
US20130230499A1 (en) * 2010-03-10 2013-09-05 Michal Eisenbach-Schwartz Cellular blood markers for early diagnosis of als and for als progression
WO2012004276A2 (en) * 2010-07-06 2012-01-12 Fondazione Telethon Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
JP5801895B2 (ja) * 2011-08-12 2015-10-28 株式会社Lsiメディエンス 全身性炎症反応症候群を伴わない術後感染症の検出方法
CA2851280C (en) * 2011-10-11 2021-05-18 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
WO2014102333A1 (en) * 2012-12-28 2014-07-03 Mitsubishi Chemical Medience Corporation Use of scd14 or its fragments or derivatives for risk stratisfaction, diagnosis and prognosis
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物
WO2016083374A1 (en) * 2014-11-25 2016-06-02 F. Hoffmann-La Roche Ag Biomarkers of fast progression of chronic kidney disease
SG11201808671YA (en) * 2015-04-02 2018-11-29 Methodist Hospital Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
EP3391057B1 (en) * 2015-12-16 2020-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
US11131676B2 (en) * 2016-02-25 2021-09-28 The Trustees Of Columbia University In The City Of New York Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
EP3612566A4 (en) 2017-04-21 2021-03-03 Implicit Bioscience Limited CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Also Published As

Publication number Publication date
IL278616B2 (en) 2025-02-01
JP2021523375A (ja) 2021-09-02
AU2019264996A1 (en) 2020-11-26
JP7371019B2 (ja) 2023-10-30
IL278616B1 (en) 2024-10-01
WO2019217916A1 (en) 2019-11-14
CN112424608A (zh) 2021-02-26
KR20210014109A (ko) 2021-02-08
JP2023181255A (ja) 2023-12-21
US20210231686A1 (en) 2021-07-29
EP3791188A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
BR112021012222A2 (https=)
BR112021008873A2 (https=)
BR122022006221A2 (https=)
BR122022015534A2 (https=)
BR122022002075A2 (https=)
IL278616A (https=)
AT521543A3 (https=)
BR122022005529A2 (https=)
BR122022016585A2 (https=)
BR212020012832U2 (https=)
BR202018071071U8 (https=)
BR202018008879U2 (https=)
BR202018007669U2 (https=)
BR202018006247U2 (https=)
BR202018004136U2 (https=)
BR202018002487U2 (https=)
BR202018002069U2 (https=)
CN304437412S (https=)
CN304434110S (https=)
CN304388867S9 (https=)
CN304267588S9 (https=)
CN304201967S8 (https=)
CN303588531S9 (https=)
CN303584708S8 (https=)
CN303562894S9 (https=)